IP Library Granted Patent US 8,741,970
Granted Patent B2
US 8,741,970 · App. 13/325,842 · Granted Jun 3, 2014

Composition and method for the enhancement of the efficacy of drugs

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,741,970
App. No.
13/325,842
Granted
Jun 3, 2014
Kind
B2
Abstract

The present invention relates to the enhancement of the efficacy of drugs, and more particularly, with overcoming the resistance of cells or organisms to drugs. In particular, the present invention provides a method for enhancing the effectiveness of a cytotoxic or anti-neoplastic agent, comprising the step of co-administering said agent with hyaluronan, wherein co-administration with hyaluronan enhances the agent's cancer cell-killing potential.

Claims (6)

1. A pharmaceutical composition comprising hyaluronan and an anticancer chemotherapeutic agent, wherein said composition is administered intravenously, the concentration of said hyaluronan is ≧1 gram per liter, and wherein the hyaluronan has a molecular weight of about 890 KDa.

2. The pharmaceutical composition of claim 1 , wherein the hyaluronan elutes within ±10 ml of the fraction with a molecular weight of 890 KDa as analyzed on a Sephacryl S-1000 1.6 cm×70 cm size exclusion gel column with a fraction size of 2 ml and flow rate of 18 ml/h.

3. The pharmaceutical composition of claim 1 , wherein the hyaluronan has a polydispersity of 1.78.

4. The pharmaceutical composition of claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of methotrexate, paclitaxel, 5-fluorouracil and cyclophosphamide or combinations thereof.

5. The pharmaceutical composition of claim 1 , wherein the chemotherapeutic agent is cyclophosphamide.

6. The pharmaceutical composition of claim 1 , wherein the chemotherapeutic agent is paclitaxel.

Assignments (4)
CORRECTION OF EXECUTION DATE, PREVIOUSLY RECORDED AT 027531/0604 Recorded Oct 3, 2012
From: ALCHEMIA ONCOLOGY LIMITED
To: ALCHEMIA ONCOLOGY PTY LIMITED
Reel/Frame 029074/0341 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2012
From: BROWN, TRACEY
To: MEDITECH RESEARCH LIMITED
Reel/Frame 027525/0093 →
CHANGE OF NAME Recorded Jan 12, 2012
From: MEDITECH RESEARCH LIMITED
To: ALCHEMIA ONCOLOGY LIMITED
Reel/Frame 027525/0199 →
CHANGE OF NAME Recorded Jan 12, 2012
From: ALCHEMIA ONCOLOGY LIMITED
To: ALCHEMIA ONCOLOGY PTY LIMITED
Reel/Frame 027531/0604 →